本帖最后由 老马 于 2012-1-13 21:20 编辑
7 L' P* ]' L6 S9 S/ s; A# l" Y3 l+ N
爱必妥和阿瓦斯丁的比较
4 \# U) L' x2 Q& v
' V) q5 C8 ] [0 s% c5 u8 \4 Xhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
7 p8 L5 ^1 P$ D; A
# |8 a+ h; w4 ^+ h5 X/ A, Y
6 `. I7 e( |! {/ o0 x4 ?( yhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
% {8 S, x# {7 f7 v( U8 }1 ?$ n7 n==================================================, @3 Q8 T- B p/ D
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# [9 b) G' a0 X! u% N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: w" o. ?) q3 p6 B4 x* f5 |9 xResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 i3 T0 a3 |; e1 u0 b1 f
|